Revenio Group OyjREVXF 82 Net Current Asset Value is $0.85 as of Mar. 2026, which is 98% below its 10-year median of 49.42. GuruFocus rates REVXF with a GF Score™ of 82/100 and a GF Value™ of $40.83 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Revenio Group Oyj ranks worse than 85.06% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Revenio Group Oyj's net current asset value per share for the quarter that ended in Mar. 2026 was $0.85.
The historical rank and industry rank for Revenio Group Oyj's Net Current Asset Value or its related term are showing as below:
REVXF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 16.86 Med: 49.42 Max: 552
Current: 16.92
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Revenio Group Oyj was 552.00. The lowest was 16.86. And the median was 49.42.
REVXF's Price-to-Net-Current-Asset-Value is ranked worse than 85.06% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.99
vs REVXF: 16.92
Revenio Group Oyj (OTCPK:REVXF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Revenio Group Oyj Net Current Asset Value Related Terms
Revenio Group Oyj Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Revenio Group Oyj's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
REVXF vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Revenio Group Oyj's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revenio Group Oyj Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Revenio Group Oyj's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.85 mean?
Revenio Group Oyj (REVXF) has a Net Current Asset Value of $0.85 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Revenio Group Oyj and its competitors. This is 98% below median its historical median of 49.42. Over the past decade, Revenio Group Oyj's Net Current Asset Value has ranged from 16.86 to 552.00. According to the industry distribution chart, Revenio Group Oyj ranks #484 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 85.1%.
Is Revenio Group Oyj's Net Current Asset Value too high?
Revenio Group Oyj's current Net Current Asset Value of $0.85 is 98% below median its 10-year median of 49.42. Over the past 10 years, this metric has ranged from a low of 16.86 to a high of 552.00. The Medical Devices & Instruments industry median Net Current Asset Value is 4.99. Revenio Group Oyj's value of $0.85 is 83% below this industry median. Based on the distribution chart, Revenio Group Oyj ranks #484 out of 569 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Revenio Group Oyj has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Revenio Group Oyj ranks #484 out of 569 companies for Net Current Asset Value. This places Revenio Group Oyj in the lower half of its industry. The industry median Net Current Asset Value is 4.99. Revenio Group Oyj's value of $0.85 is 83% below this benchmark. Historically, Revenio Group Oyj's own Net Current Asset Value has ranged from 16.86 to 552.00 over the past decade. While the company's 10-year median is 49.42 vs. the industry median of 4.99, Revenio Group Oyj has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.99, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current Net Current Asset Value of $0.85 is 83% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Revenio Group Oyj and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current Net Current Asset Value is $0.85, which is 98% below median its own 10-year median of 49.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (REVXF) is currently considered Significantly Undervalued. The stock's GF Value™ is $40.83, compared to a current price of $16.41 — trading 59.8% below its estimated fair value. The current Net Current Asset Value is $0.85, which is 98% below median its 10-year median of 49.42 and 83% below the Medical Devices & Instruments industry median of 4.99. Revenio Group Oyj's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Revenio Group Oyj (REVXF), the current Net Current Asset Value is $0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revenio Group Oyj (REVXF) Overvalued in 2026?
Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued.
The current stock price of $16.41 is trading 59.8% below its estimated GF Value™ of $40.83.
GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.
Key valuation signals for REVXF:
Net Current Asset Value: $0.85 (98% below median its 10-year median of 49.42)
GF Value™: $40.83 vs. price of $16.41 (59.8% below fair value)
Industry Position: 83% below the Medical Devices & Instruments median (#484 of 569)
No single metric tells the full story. See the REVXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
82GF Score
Get the complete analysis for REVXF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
REVXF has been successfully added to your 
